# OnCo record dat-2645 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dat-2645/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dat-2645" ;
  schema:name "DAT-2645"@en ;
  schema:description "DAT-2645 is an experimental small molecule from Danatlas Pharmaceuticals, in phase 2 trials for solid tumours with BRCA1/2 or DNA damage repair defects and BRCA-mutated or HRD-positive ovarian cancer."@en ;
  schema:url <https://onco.cc/drugs/dat-2645/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/api/v2/studies/NCT06614751>, <https://clinicaltrials.gov/api/v2/studies/NCT07652073>, <https://clinicaltrials.gov/search?intr=DAT-2645> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Small molecule (oral tablet)" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/parg/> ;
  onco:companies <https://onco.cc/companies/danatlas-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct06614751/>, <https://onco.cc/trials/nct07652073/> .